Diabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatment

dc.contributor.affiliationUniversidade de Santiago de Compostela. Departamento de Farmacoloxía, Farmacia e Tecnoloxía Farmacéuticagl
dc.contributor.authorKattar, Axel
dc.contributor.authorConcheiro Nine, Ángel Joaquín
dc.contributor.authorÁlvarez Lorenzo, Carmen
dc.date.accessioned2023-03-27T11:01:17Z
dc.date.available2023-03-27T11:01:17Z
dc.date.issued2021
dc.description.abstractIntroduction: Diabetes is a pandemic disease that causes relevant ocular pathologies. Diabetic retinopathy, macular edema, cataracts, glaucoma, or keratopathy strongly impact the quality of life of the patients. In addition to glycemic control, intense research is devoted to finding more efficient ocular drugs and improved delivery systems that can overcome eye barriers. Areas covered: The aim of this review is to revisit first the role of diabetes in the development of chronic eye diseases. Then, commercially available drugs and new candidates in clinical trials are tackled together with the pros and cons of their administration routes. Subsequent sections deal with self-assembled drug carriers suitable for eye instillation combining patient-friendly administration with high ocular bioavailability. Performance of topically administered polymeric micelles, liposomes, and niosomes for the management of diabetic eye diseases is analyzed in the light of ex vivo and in vivo results and outcomes of clinical trials. Expert opinion: Self-assembled carriers are being shown useful for efficient delivery of not only a variety of small drugs but also macromolecules (e.g. antibodies) and genes. Successful design of drug carriers may offer alternatives to intraocular injections and improve the treatment of both anterior and posterior segments diabetic eye diseasesgl
dc.description.peerreviewedSIgl
dc.description.sponsorshipThis project is funded by Horizon 2020 Marie Sklodowska-Curie Actions [grant agreement – No 813440]gl
dc.identifier.citationExpert Opinion on Drug Delivery, 18:11, 1589-1607 (2021)gl
dc.identifier.doi10.1080/17425247.2021.1953466
dc.identifier.issn1742-5247
dc.identifier.urihttp://hdl.handle.net/10347/30387
dc.language.isoenggl
dc.publisherTaylor & Francisgl
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/H2020/813440-ORBITAL-Ocular Research by Integrated Training and Learninggl
dc.relation.publisherversionhttps://doi.org/10.1080/17425247.2021.1953466gl
dc.rights© 2021 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any waygl
dc.rights.accessRightsopen accessgl
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectDiabetic eyegl
dc.subjectTopical ocular deliverygl
dc.subjectLiposomesgl
dc.subjectPolymeric micellesgl
dc.subjectNiosomesgl
dc.subjectClinical trialsgl
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320901 Análisis de medicamentosgl
dc.subject.classificationMaterias::Investigación::32 Ciencias médicas::3209 Farmacología::320908 Preparación de medicamentosgl
dc.titleDiabetic eye: associated diseases, drugs in clinic, and role of self-assembled carriers in topical treatmentgl
dc.typejournal articlegl
dc.type.hasVersionVoRgl
dspace.entity.typePublication
relation.isAuthorOfPublicationfbd9d3a4-b1f4-4aff-8472-de22b1c140c4
relation.isAuthorOfPublication44d6632e-65cd-485a-bb67-86df5567793a
relation.isAuthorOfPublication.latestForDiscoveryfbd9d3a4-b1f4-4aff-8472-de22b1c140c4

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Expert Opin Drug Del 18, 1589-1607 (2021).pdf
Size:
3.96 MB
Format:
Adobe Portable Document Format
Description: